NYSE ARCA | ETF
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index.
The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
Top 20 Holdings
Asset | Name | Sector | Industry | Weight |
---|---|---|---|---|
ALPN | Alpine Immune Sciences Inc | Healthcare | Biotechnology | 2.68% |
NVAX | Novavax Inc | Healthcare | Biotechnology | 2.12% |
GERN | Geron Corporation | Healthcare | Biotechnology | 1.84% |
MORF | Morphic Holding Inc | Healthcare | Biotechnology | 1.58% |
LBPH | Longboard Pharmaceuticals Inc | Healthcare | Biotechnology | 1.31% |
KRYS | Krystal Biotech Inc | Healthcare | Biotechnology | 1.28% |
NK | NantKwest Inc | Healthcare | Biotechnology | 1.23% |
QURE | Uniqure NV | Healthcare | Biotechnology | 1.19% |
ANAB | AnaptysBio Inc | Healthcare | Biotechnology | 1.18% |
ORIC | Oric Pharmaceuticals Inc | Healthcare | Biotechnology | 1.14% |
IGMS | IGM Biosciences Inc | Healthcare | Biotechnology | 1.13% |
ERAS | Erasca Inc | Healthcare | Biotechnology | 1.11% |
KRTX | Karuna Therapeutics Inc | Healthcare | Biotechnology | 1.10% |
CBAY | Cymabay Therapeu | Healthcare | Biotechnology | 1.09% |
VERV | Verve Therapeutics Inc | Healthcare | Biotechnology | 1.07% |
PHAT | Phathom Pharmaceuticals Inc | Healthcare | Biotechnology | 1.06% |
NRIX | Nurix Therapeutics Inc | Healthcare | Biotechnology | 1.05% |
INBX | Inhibrx Inc | Healthcare | Biotechnology | 1.04% |
ALEC | Alector Inc | Healthcare | Biotechnology | 1.04% |
DYN | Dyne Therapeutics Inc | Healthcare | Biotechnology | 1.01% |